Cannabinoids show promise in fighting brain cancer when combined with chemotherapy

Researchers investigated how cannabinoids could help treat glioblastoma, one of the deadliest brain tumors with a median survival time of only 12-15 months. The study focused on how CBD, THC, and cannabis flower extract (CFE) affect the tumor at the epigenetic level—essentially how these compounds change the chemical markers on DNA without altering the genetic code itself. Using advanced laboratory techniques, scientists measured changes in m5C (a key DNA methylation marker) and 8-oxo-dG (an indicator of oxidative stress), both crucial indicators of how cancer cells behave.

The key finding is that cannabinoids alone, and especially when combined with temozolomide (TMZ)—the current standard chemotherapy drug—effectively inhibited glioblastoma progression in laboratory settings. The research reveals that phytocannabinoids work as epigenetic regulators by managing the tumor cell's redox homeostasis (its ability to balance reactive oxygen species). This mechanism suggests that cannabinoids could enhance the effectiveness of existing glioblastoma treatments by working synergistically with conventional chemotherapy.

While these are promising early findings, it's important to note this is laboratory research that requires further development before clinical applications. The discovery that cannabinoids can modify epigenetic markers and work alongside standard cancer treatments opens a new avenue for glioblastoma research and could eventually lead to more effective therapeutic options for patients facing this devastating disease.